Stefan Grass
Plus aucun poste en cours
Fortune : 66 695 $ au 31/03/2024
Profil
Stefan Grass worked as a Medical Officer at CSL Behring AB.
He also served as the Chief Medical & Technology Officer at Bactiguard Holding AB from 2019 to 2020.
Dr. Grass obtained his graduate and doctorate degrees from Karolinska Institutet.
Détentions connues dans des sociétés publiques
Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
---|---|---|---|---|
BACTIGUARD HOLDING AB
0,03% | 31/12/2022 | 9 850 ( 0,03% ) | 66 695 $ | 31/03/2024 |
Anciens postes connus de Stefan Grass
Sociétés | Poste | Fin |
---|---|---|
CSL Behring AB
CSL Behring AB Pharmaceuticals: MajorHealth Technology CSL Behring AB develops, manufactures, and markets protein-based therapies in the bleeding disorders, critical care, immunoglobulins, and pulmonary areas. It offers therapies such as plasma-derived and recombinant coagulation factors, immunoglobulins for the treatment of primary immune deficiency, alpha1-proteinase inhibitor for chronic A1-PI augmentation therapy, and C1-INH concentrate. The company was founded in 1904 and is headquartered in Danderyd, Sweden. | Corporate Officer/Principal | - |
BACTIGUARD HOLDING AB | Chief Tech/Sci/R&D Officer | - |
Formation de Stefan Grass
Karolinska Institutet | Doctorate Degree |
Expériences
Fonctions occupées
Sociétés liées
Sociétés cotées | 1 |
---|---|
BACTIGUARD HOLDING AB | Health Technology |
Entreprise privées | 1 |
---|---|
CSL Behring AB
CSL Behring AB Pharmaceuticals: MajorHealth Technology CSL Behring AB develops, manufactures, and markets protein-based therapies in the bleeding disorders, critical care, immunoglobulins, and pulmonary areas. It offers therapies such as plasma-derived and recombinant coagulation factors, immunoglobulins for the treatment of primary immune deficiency, alpha1-proteinase inhibitor for chronic A1-PI augmentation therapy, and C1-INH concentrate. The company was founded in 1904 and is headquartered in Danderyd, Sweden. | Health Technology |